New combo therapy targets unresectable liver cancer
NCT ID NCT07281664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination treatment for people with advanced liver cancer that cannot be surgically removed. The treatment includes a procedure that delivers chemotherapy directly to the tumor (TACE) plus two drugs that boost the immune system and block blood vessel growth. The goal is to see if this approach can shrink tumors and help patients live longer, while monitoring side effects. About 30 adults aged 18 to 75 with good liver function and no prior systemic therapy will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?